Do not stop or change your medication without speaking to a pharmacist or healthcare professional.
Active Shortage

PMS-IRBESARTAN-HCTZ

PHARMASCIENCE INC

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of PMS-IRBESARTAN-HCTZ in Canada?

Yes. PMS-IRBESARTAN-HCTZ 12.5MG 300MG has an active shortage reported to Health Canada (last updated October 5, 2026).

Why is PMS-IRBESARTAN-HCTZ not available?

The reason the manufacturer reported: Disruption of the manufacture of the drug.

When will PMS-IRBESARTAN-HCTZ be available again?

The manufacturer's estimated resolution date is December 31, 2027. This is an estimate and can change; follow this page to get an email when the status changes.

Can I still get this?Check with your pharmacist
StatusActive Shortage
Same-ingredient products on fileNone found
Expected resolution~14 months remaining (estimate)
Affected strength12.5MG 300MG
Report last updated2026-10-05
Checked by MedShort2026-11-12

What this means

Does this mean my pharmacy is out of stock?

Not necessarily — a national shortage doesn't mean every pharmacy has run out. Some locations may still have stock, especially of a specific strength or pack size.

What should I do?

Contact your pharmacy before your current supply runs low, and ask your pharmacist about next steps if they're out.

Estimated Resolution

2027-12-31

~14 months remaining (estimate)

This is the manufacturer's estimated date, not a guarantee — actual resolution may come earlier or later.

Have you checked a pharmacy recently?

No community reports yet — be the first to share what you found.

Community reports are not verified by a pharmacy and may reflect a small sample size. This is not a guarantee of current stock.

DIN

02328526

Strength

12.5MG 300MG

Dosage Form

TABLET

Route

ORAL

Active Ingredient

HYDROCHLOROTHIAZIDE IRBESARTAN

Tier

Unrated

Last Updated

2026-10-05

Reason for Shortage

Disruption of the manufacture of the drug.